Blueprint Medicines (NASDAQ:BPMC) Sets New 52-Week High at $107.56

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as $107.56 and last traded at $107.00, with a volume of 391291 shares trading hands. The stock had previously closed at $94.86.

Analyst Ratings Changes

A number of brokerages recently commented on BPMC. HC Wainwright reissued a "buy" rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, April 26th. Wedbush reiterated an "outperform" rating and set a $110.00 price objective on shares of Blueprint Medicines in a report on Friday, April 26th. Citigroup increased their price objective on shares of Blueprint Medicines from $54.00 to $65.00 and gave the stock a "sell" rating in a report on Friday, February 16th. Needham & Company LLC reiterated a "buy" rating and set a $97.00 price objective on shares of Blueprint Medicines in a report on Thursday. Finally, JMP Securities reiterated a "market outperform" rating and set a $114.00 price objective on shares of Blueprint Medicines in a report on Wednesday, April 10th. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines currently has a consensus rating of "Hold" and an average price target of $91.57.

Blueprint Medicines Price Performance

The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66. The firm has a market cap of $6.55 billion, a price-to-earnings ratio of -12.33 and a beta of 0.65. The business's 50-day moving average price is $91.00 and its two-hundred day moving average price is $79.92.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping analysts' consensus estimates of ($2.04) by $0.22. The firm had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm's revenue was up 85.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.65) earnings per share. On average, research analysts forecast that Blueprint Medicines Co. will post -5.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Christopher K. Murray sold 621 shares of the firm's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $93.65, for a total value of $58,156.65. Following the sale, the insider now directly owns 36,374 shares in the company, valued at $3,406,425.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Christopher K. Murray sold 621 shares of Blueprint Medicines stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now directly owns 36,374 shares of the company's stock, valued at $3,406,425.10. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Christopher K. Murray sold 5,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total value of $500,000.00. Following the transaction, the insider now directly owns 24,495 shares in the company, valued at $2,449,500. The disclosure for this sale can be found here. Insiders sold a total of 92,289 shares of company stock valued at $8,314,163 over the last 90 days. 3.88% of the stock is owned by company insiders.

Hedge Funds Weigh In On Blueprint Medicines

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its stake in Blueprint Medicines by 1.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company's stock valued at $13,396,000 after acquiring an additional 4,127 shares in the last quarter. Brown Advisory Inc. lifted its holdings in shares of Blueprint Medicines by 0.9% during the 3rd quarter. Brown Advisory Inc. now owns 641,039 shares of the biotechnology company's stock valued at $32,193,000 after buying an additional 5,843 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Blueprint Medicines by 9.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,055 shares of the biotechnology company's stock valued at $605,000 after buying an additional 1,052 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Blueprint Medicines by 4.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,269 shares of the biotechnology company's stock worth $1,872,000 after purchasing an additional 1,417 shares during the last quarter. Finally, Emerald Advisers LLC lifted its holdings in Blueprint Medicines by 22.4% in the 3rd quarter. Emerald Advisers LLC now owns 607,037 shares of the biotechnology company's stock worth $30,485,000 after purchasing an additional 110,984 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.